Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Fernando Bril MD

Fernando Bril MD

Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama

Originally from Argentina, where he did his medical school and internal medicine residency, Dr. Bril moved to USA in 2012. Since then, he has completed a second internal medicine residency, and has been working as a physician-scientist in the field of NAFLD and insulin resistance. Even before starting his Internal Medicine residency, Dr. Bril had a strong interest in clinical research and biostatistics, embarking early-on on a career as a physician-scientist. Dr. Bril’s main research interest has been to understand the metabolic mechanisms that promote the progression from isolated steatosis to NASH and to identify pharmacological approaches that could be used to delay this progression. He has carried out several clinical and translational research studies that have resulted in significant peer-reviewed articles in the field, including 2 randomized controlled trials on the use of pioglitazone alone or combined with vitamin E (Cusi, et al. Annals Intern Med 2016; Bril, et al. Diabetes Care 2019). More specifically, in the last few years, he has carefully examined how the severity of liver disease influences changes in dyslipidemia, diabetes control, and insulin resistance, all mechanisms potentially leading to the increased cardiovascular risk in patients with NAFLD. Dr. Bril and his research group have also focused on the assessment of potential new plasma and imaging biomarkers for the diagnosis of NAFLD.


Dr. Bril has nothing to disclose.